Eli Lilly & Co. has surged about 300% since its first GLP-1 was approved over four years ago, propelling it past $1 trillion in market value and making it the world’s most valuable pharmaceutical company.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.